The Utility of Data Tokenization in Clinical Trials
With the growing rate of real-world data (RWD) sources and the evolution of data technologies, it is essential to understand the advantages and challenges tied to linked RWD. In a study conducted by Boehringer Ingelheim and Science 37, they showed nearly 90% overlap between trial patient cohort and real-world datasets, even with small trial populations.
Learn how tokenization enables:
- Connecting diverse data sources to your clinical trials
- Protecting personally identifiable information
- Earlier access to real-world data
See how Datavant can link data directly into clinical trials, providing the potential to validate real world populations prior to marketing authorization.